The role of prescription drugs in female overactive bladder syndrome-A population-wide cohort study.
drug interactions
drug utilization
overactive bladder
pharmacoepidemiology
polypharmacy
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
04
03
2019
revised:
13
09
2019
accepted:
12
10
2019
pubmed:
7
12
2019
medline:
23
1
2021
entrez:
7
12
2019
Statut:
ppublish
Résumé
Overactive bladder (OAB) syndrome has severe effects on quality of life. Certain drugs are known risk factors for OAB but have not been investigated in a population-wide cohort. The objective of this study was to investigate the role of prescription drugs in the etiology of the OAB. Retrospective cohort study using a population-wide database of 4 185 098 OAB-naïve women followed Strengthening the Reporting of Observational Studies in Epidemiology guidelines. We investigated the subscription use of anticholinergic medication and 188 chemical substances, which are suspected triggers for OAB (trigger medications [TMs]). We hypothesized a relationship between the prescription for one or more TM and the prescription for anticholinergic medication against OAB (marker medication [MM]). The use of MM in Austria increased from 2009 to 2012 on average by 0.025 percentage points per year (95% confidence interval [CI]: 0.015-0.036). In December 2012, 1 in 123 women filled a prescription for any MM, equaling an average utilization of 0.84%. The relative risk of filling a prescription for a MM 6 months after filling a prescription for a TM was 2.70 (95% CI: 2.64-2.77). All investigated medication classes showed a higher risk for the prescription for MM. Medication from classes "genitourinary system and sex hormones" and "systemic anti-infectives" caused the highest increase in risk (109% and 89%, respectively). Prescriptions for class "cardiovascular system" caused the lowest increase in the risk (15%). Certain prescription medications are a significant risk factor for the need to take anticholinergic medication as a consequence.
Identifiants
pubmed: 31808271
doi: 10.1002/pds.4920
pmc: PMC7027558
doi:
Substances chimiques
Prescription Drugs
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
189-198Informations de copyright
© 2019 The Authors. Pharmacoepidemiology & Drug Safety Published by John Wiley & Sons Ltd.
Références
Eur J Clin Pharmacol. 2012 May;68(5):783-91
pubmed: 22138718
Clin Pharmacol Ther. 2002 Dec;72(6):729-34
pubmed: 12496754
Br J Clin Pharmacol. 1996 Oct;42(4):507-9
pubmed: 8904625
Pharmacoepidemiol Drug Saf. 2020 Feb;29(2):189-198
pubmed: 31808271
BMC Urol. 2013 May 30;13:27
pubmed: 23721491
Am Fam Physician. 2000 Dec 1;62(11):2433-44, 2447, 2452
pubmed: 11130230
Age Ageing. 2014 Jul;43(4):515-21
pubmed: 24334709
Can Fam Physician. 2002 Jan;48:96-101
pubmed: 11852617
Int Urogynecol J. 2010 Jan;21(1):5-26
pubmed: 19937315
Ann Pharmacother. 2016 Aug;50(8):625-36
pubmed: 27257284
J Clin Epidemiol. 2000 Nov;53(11):1150-7
pubmed: 11106889
Obstet Gynecol. 1998 May;91(5 Pt 2):853-4
pubmed: 9572189
Trends Pharmacol Sci. 1996 Sep;17(9):314-6
pubmed: 8885694
Obstet Gynecol. 2000 Sep;96(3):446-51
pubmed: 10960640
Eur Urol. 2005 Oct;48(4):622-7
pubmed: 15964133
JAMA. 2005 Feb 23;293(8):935-48
pubmed: 15728164
Rev Urol. 2008 Winter;10(1):6-13
pubmed: 18470275
J Am Geriatr Soc. 2002 Jun;50(6):1165-6
pubmed: 12110086
Nat Rev Dis Primers. 2017 Jul 06;3:17042
pubmed: 28681849
Am J Epidemiol. 2011 May 1;173(9):1022-31
pubmed: 21357657
Arch Gerontol Geriatr. 2009 Jul-Aug;49(1):64-8
pubmed: 18752858
Am J Obstet Gynecol. 2001 Jul;185(1):62-4
pubmed: 11483905
Pharmacoepidemiol Drug Saf. 2016 Jan;25(1):90-9
pubmed: 26468002
Lancet. 2000 Aug 12;356(9229):568
pubmed: 10950240
BMC Geriatr. 2013 Jun 10;13:57
pubmed: 23758756